ACAT1 and Checkpoint Inhibitor Combination for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, particularly checkpoint inhibitors, face limitations in effectively targeting and eliminating cancer cells due to the suppressive mechanisms employed by cancer cells, which hinder the immune system's ability to recognize and attack these cells.
Innovation Solution
Combining an immune checkpoint inhibitor with an acyl-coenzyme A:cholesterol acyltransferases 1 (ACAT1) inhibitor, such as avasimibe, to enhance the antitumor efficacy by potentiating the effector function of CD8+ T cells and increasing their cytotoxic activity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to block immune checkpoint molecules, then T cell recognition and attack of cancer cells is enhanced, but the antitumor efficacy is limited by the suppressive mechanisms of cancer cells
Solution Approach 1:
The patent combines checkpoint inhibitors with ACAT1 inhibitors to create a synergistic therapy. The ACAT1 inhibitor disrupts cholesterol metabolism in cancer cells, while the checkpoint inhibitor removes immune suppression, together achieving enhanced antitumor efficacy that surpasses monotherapy approaches.
Solution Approach 2:
The ACAT1 inhibitor alters the cholesterol metabolism parameters of cancer cells, changing their physical and chemical state to make them more vulnerable to immune attack. This parameter change in cancer cell metabolism enhances the effectiveness of the checkpoint inhibitor.
2Reliability
If monotherapy with checkpoint inhibitors is administered, then treatment simplicity is maintained, but antitumor activity is insufficient
Solution Approach 1:
The patent merges two therapeutic agents - ACAT1 inhibitor and checkpoint inhibitor - into a combination therapy. This combination achieves superior antitumor activity compared to either agent alone, while the dosing and administration remain manageable through standardized protocols.
Data Source
AI summary
The present disclosure provides methods and compositions for the treatment of cancer using an ACAT1 inhibitor in combination with an immune checkpoint inhibitor. The immune checkpoint inhibitor may inhibit the programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof. The ACAT1 inhibitor may be avasimibe, pactimibe, or purpactins, without limitation.